story of the week
Trastuzumab Deruxtecan in Advanced HER2+ Breast Cancer Previously Treated With Trastuzumab Emtansine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Deruxtecan (DS-8201a) in Patients With Advanced HER2-Positive Breast Cancer Previously Treated With Trastuzumab Emtansine: A Dose-Expansion, Phase 1 Study
Lancet Oncol 2019 Apr 29;[EPub Ahead of Print], K Tamura, J Tsurutani, S Takahashi, H Iwata, IE Krop, C Redfern, Y Sagara, T Doi, H Park, RK Murthy, RA Redman, T Jikoh, C Lee, M Sugihara, J Shahidi, A Yver, S ModiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.